# Medicines and Healthcare products Regulatory Agency

### MANUFACTURER'S AUTHORISATION

1: Authorisation Number UK MIA(IMP) 3473

2: Name of authorisation holder NHS NATIONAL SERVICES SCOTLAND

NHS NATIONAL SERVICES SCOTLAND, THE JACK COPLAND CENTRE, 52

RESEARCH AVENUE NORTH, HERIOT-WATT RESEARCH PARK,

RICCARTON, CURRIE, EH14 4BE, UNITED KINGDOM

3: Address(es) of manufacturing site(s) INSTITUTE FOR REGENERATION AND REPAIR - NORTH, GMP CELLULAR

THERAPY FACILITY, SCOTTISH CENTRE FOR REGENERATIVE MEDICINE, EDINBURGH BIOQUARTER, 5 LITTLE FRANCE DRIVE, EDINBURGH, EH16

4UU, UNITED KINGDOM

4: Legally registered address of authorisation

RESEARCH AVENUE NORTH, HERIOT-WATT RESEARCH PARK,

RICCARTON, CURRIE, EH14 4BE, UNITED KINGDOM

5: Scope of authorisation and dosage forms ANNEX 1 and/ or ANNEX 2

6: Legal Basis of authorisation

Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 [SI

2004/1031]

7: Name of responsible officer of the competent

authority of the member state granting the

manufacturing authorisation

Confidential

8: Authorisation Date 07/01/2025

9: Annexes attached Annex 1 and/or Annex 2

#### SCOPE OF AUTHORISATION

### Annex 2

holder

Name and address of the site:

NHS NATIONAL SERVICES SCOTLAND, THE JACK COPLAND CENTRE, 52 RESEARCH AVENUE NORTH, HERIOT-WATT RESEARCH PARK, RICCARTON, CURRIE, EH14 4BE, UNITED KINGDOM

Human Investigational Medicinal Products

**Authorised Operations** 

MANUFACTURING OPERATIONS (according to part 1)

#### Part 1 - MANUFACTURING OPERATIONS

[ 1.1 ] Sterile Investigational Medicinal Products

[1.1.1] Aseptically prepared (processing operations for the following dosage forms)

Issue Date: 07 Jan 2025

[1.1.1.6] Other aseptically prepared products
Human derived ATMPs as stipulated in 1394/2007. Cell banking of cells of human origin.

[1.3] Biological investigational medicinal products
[1.3.1] Biological medicinal products
[1.3.1.3] Cell therapy products
[1.3.1.4] Gene therapy products
[1.3.1.8] Other biological medicinal products
Human derived ATMPs as stipulated in 1394/2007. Cell banking of cells of human origin.

[1.5] Packaging
[1.5.1] Primary packaging
[1.5.1.6] Liquids for internal use
[1.5.2] Secondary packaging
[1.6.0] Quality control testing
[1.6.2] Microbiological: non-sterility

### SCOPE OF AUTHORISATION

#### Annex 2

Name and address of the site:

[1.6.3] Chemical/Physical

[1.6.4] Biological

INSTITUTE FOR REGENERATION AND REPAIR - NORTH, GMP CELLULAR THERAPY FACILITY, SCOTTISH CENTRE FOR REGENERATIVE MEDICINE, EDINBURGH BIOQUARTER, 5 LITTLE FRANCE DRIVE, EDINBURGH, EH16 4UU, UNITED KINGDOM

**Human Investigational Medicinal Products** 

**Authorised Operations** 

MANUFACTURING OPERATIONS (according to part 1)

### Part 1 - MANUFACTURING OPERATIONS

#### [ 1.1 ] Sterile Investigational Medicinal Products

[ 1.1.1 ] Aseptically prepared (processing operations for the following dosage forms)

[ 1.1.1.6 ] Other aseptically prepared products

Human derived ATMPS as stipulated in 1394/2007

#### [ 1.3 ] Biological investigational medicinal products

[ 1.3.1 ] Biological medicinal products

[1.3.1.3] Cell therapy products

[1.3.1.4] Gene therapy products

[ 1.3.1.6 ] Human or animal extracted products

[ 1.3.1.8 ] Other biological medicinal products

Cell banking of cells of human origin

#### [ 1.5 ] Packaging

[1.5.1] Primary packaging

[1.5.1.6] Liquids for internal use

Issue Date: 07 Jan 2025

[ 1.5.2 ] Secondary packaging

## [ 1.6 ] Quality control testing

[ 1.6.2 ] Microbiological: non-sterility

[ 1.6.3 ] Chemical/Physical

[ 1.6.4 ] Biological

